Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

High-Risk Localized Prostate Cancer × darolutamide × 30 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13 Urogenital Neoplasms 2 Biochemically Recurrent Prostate Cancer 2 Urogenital Diseases 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Non-metastatic Castration-resistant Prostate Cancer 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Male Urogenital Diseases 1 High-Risk Localized Prostate Cancer 1 Granulosa cell tumor of the ovary 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07450599 2026-03-05

CHINANEO

Bayer

Phase 2 Not yet recruiting

High-Risk Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡